{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:15:50Z","timestamp":1793646950718,"version":"4.5.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010607","name":"Universit\u00e0 degli Studi di Perugia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010607","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Aicardi\u2013Gouti\u00e8res syndrome (AGS) is a genetically determined disorder with a variable phenotype. Since the original description of AGS, advances in gene sequencing techniques have resulted in a significant broadening of the phenotypic spectrum associated with <jats:italic>AGS<\/jats:italic> genes, and new clinical pictures have emerged beyond the classic presentation. The aim of this review is to provide a comprehensive analysis of the clinical spectrum of AGS and report currently available treatments and new immunosuppressive strategies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Data sources<\/jats:title>\n                <jats:p>Literature reviews and original research articles were collected from databases, including PubMed and ClinicalTrials.gov. Relevant articles about AGS were included.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The involvement of the nervous system certainly represents the major cause of mortality and morbidity in AGS patients. However, other clinical manifestations, such as chilblains, hepatosplenomegaly, and hematological disturbances, may lead to the diagnosis and considerably impact the prognosis and overall quality of life of these patients. Therapeutic approaches of AGS are limited to interventions aimed at specific symptoms and the management of multiple comorbidities. However, advances in understanding the pathogenesis of AGS could open new and more effective therapies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The over-activation of innate immunity due to upregulated interferon production plays a critical role in AGS, leading to multi-organ damage with the main involvement of the central nervous system. To date, there is no specific and effective treatment for AGS. New drugs specifically targeting the interferon pathway may bring new hope to AGS patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12519-022-00679-2","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T17:02:48Z","timestamp":1673974968000},"page":"635-643","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Clinical spectrum and currently available treatment of type I interferonopathy\u00a0Aicardi\u2013Gouti\u00e8res syndrome"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2302-1029","authenticated-orcid":false,"given":"Giovanni Battista","family":"Dell\u2019Isola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleb Logan","family":"Culpepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherin Elizabeth","family":"Portwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Di Cara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Verrotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Lodolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"679_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/ana.410150109","volume":"15","author":"J Aicardi","year":"1984","unstructured":"Aicardi J, Gouti\u00e8res F. A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol. 1984;15:49\u201354.","journal-title":"Ann Neurol"},{"key":"679_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ajmg.a.36887","volume":"167A","author":"YJ Crow","year":"2015","unstructured":"Crow YJ, Chase DS, Lowenstein Schmidt J, Szynkiewicz M, Forte GMA, Gornall HL, et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet Part A. 2015;167A:296\u2013312.","journal-title":"Am J Med Genet Part A"},{"key":"679_CR3","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41588-020-00737-3","volume":"52","author":"C Uggenti","year":"2020","unstructured":"Uggenti C, Lepelley A, Depp M, Badrock AP, Rodero MP, El-Daher MT, et al. cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing. Nat Genet. 2020;52:1364\u201372.","journal-title":"Nat Genet"},{"key":"679_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ng.2933","volume":"46","author":"GI Rice","year":"2014","unstructured":"Rice GI, Del Toro DY, Jenkinson EM, Forte GMA, Anderson BH, Ariaudo G, et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet. 2014;46:503\u20139.","journal-title":"Nat Genet"},{"key":"679_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1055\/s-2007-973555","volume":"29","author":"M McEntagart","year":"1998","unstructured":"McEntagart M, Kamel H, Lebon P, King MD. Aicardi-Goutieres syndrome: an expanding phenotype. Neuropediatrics. 1998;29:163\u20137.","journal-title":"Neuropediatrics"},{"key":"679_CR6","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1212\/01.WNL.0000082726.08631.E7","volume":"61","author":"N Blau","year":"2003","unstructured":"Blau N, Bonaf\u00e9 L, Kr\u00e4geloh-Mann I, Th\u00f6ny B, Kierat L, H\u00e4usler M, et al. Cerebrospinal fluid pterins and folates in Aicardi-Gouti\u00e8res syndrome: a new phenotype. Neurology. 2003;61:642\u20137.","journal-title":"Neurology"},{"key":"679_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1055\/s-0036-1592307","volume":"47","author":"JH Livingston","year":"2016","unstructured":"Livingston JH, Crow YJ. Neurologic phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1: Aicardi-Gouti\u00e8res syndrome and beyond. Neuropediatrics. 2016;47:355\u201360.","journal-title":"Neuropediatrics"},{"key":"679_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/dmcn.14268","volume":"62","author":"YJ Crow","year":"2020","unstructured":"Crow YJ, Shetty J, Livingston JH. Treatments in Aicardi-Gouti\u00e8res syndrome. Dev Med Child Neurol. 2020;62:42\u20137.","journal-title":"Dev Med Child Neurol"},{"key":"679_CR9","unstructured":"Crow YJ. Aicardi-Gouti\u00e8res syndrome. 2005 Jun 29 (updated 2016 Nov 22). In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews\u00ae. Seattle (WA): University of Washington, Seattle; 1993\u20132022."},{"key":"679_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/BF02936369","volume":"32","author":"M Sata","year":"1997","unstructured":"Sata M, Yano Y, Yoshiyama Y, Ide T, Kumashiro R, Suzuki H, et al. Mechanisms of thrombocytopenia induced by interferon therapy for chronic hepatitis B. J Gastroenterol. 1997;32:206\u201310.","journal-title":"J Gastroenterol"},{"key":"679_CR11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.5414\/CNP67366","volume":"67","author":"M Espinosa","year":"2007","unstructured":"Espinosa M, Arenas MD, Aumente MD, Barril G, Buades JM, Aviles B, et al. Anemia associated with pegylated interferon-\u03b12a and \u03b12b therapy in hemodialysis patients. Clin Nephrol. 2007;67:366\u201373.","journal-title":"Clin Nephrol"},{"key":"679_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2141.1989.tb04251.x","volume":"71","author":"L Gugliotta","year":"1989","unstructured":"Gugliotta L, Bagnara GP, Catani L, Gaggioli L, Guarini A, Zauli G, et al. In vivo and in vitro inhibitory effect of \u03b1-interferon on megakaryocyte colony growth in essential thrombocythaemia. Br J Hematol. 1989;71:177\u201381.","journal-title":"Br J Hematol"},{"key":"679_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/brain\/aws321","volume":"136","author":"E Cuadrado","year":"2013","unstructured":"Cuadrado E, Jansen MH, Anink J, De Filippis L, Vescovi AL, Watts C, et al. Chronic exposure of astrocytes to interferon-\u03b1 reveals molecular changes related to Aicardi-Goutieres syndrome. Brain. 2013;136:245\u201358.","journal-title":"Brain"},{"key":"679_CR14","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1177\/0883073814562252","volume":"30","author":"A Vanderver","year":"2015","unstructured":"Vanderver A, Prust M, Kadom N, Demarest S, Crow YJ, Helman G, et al. Early-onset Aicardi-Gouti\u00e8res syndrome: magnetic resonance imaging (MRI) pattern recognition. J Child Neurol. 2015;30:1343\u20138.","journal-title":"J Child Neurol"},{"key":"679_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1469-8749.2008.03033.x","volume":"50","author":"S D\u2019arrigo","year":"2008","unstructured":"D\u2019arrigo S, Riva D, Bulgheroni S, Chiapparini L, Lebon P, Rice G, et al. Aicardi-Gouti\u00e8res syndrome: description of a late onset case. Dev Med Child Neurol. 2008;50:631\u20134.","journal-title":"Dev Med Child Neurol"},{"key":"679_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/jmedgenet-2013-102038","volume":"51","author":"JH Livingston","year":"2014","unstructured":"Livingston JH, Lin JP, Dale RC, Gill D, Brogan P, Munnich A, et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J Med Genet. 2014;51:76\u201382.","journal-title":"J Med Genet"},{"key":"679_CR17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1086\/521373","volume":"81","author":"G Rice","year":"2007","unstructured":"Rice G, Patrick T, Parmar R, Taylor CF, Aeby A, Aicardi J, et al. Clinical and molecular phenotype of Aicardi-Gouti\u00e8res syndrome. Am J Hum Genet. 2007;81:713\u201325.","journal-title":"Am J Hum Genet"},{"key":"679_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2020.10.012","volume":"115","author":"C Piccoli","year":"2021","unstructured":"Piccoli C, Bronner N, Gavazzi F, Dubbs H, De Simone M, De Giorgis V, et al. Late-onset Aicardi-Gouti\u00e8res syndrome: a characterization of presenting clinical features. Pediatr Neurol. 2021;115:1\u20136.","journal-title":"Pediatr Neurol"},{"key":"679_CR19","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/mds.21011","volume":"21","author":"K Tojo","year":"2006","unstructured":"Tojo K, Sekijima Y, Suzuki T, Suzuki N, Tomita Y, Yoshida K, et al. Dystonia, mental deterioration and dyschromatosis symmetrica hereditaria in a family with ADAR1 mutation. Mov Disord. 2006;21:1510\u20133.","journal-title":"Mov Disord"},{"key":"679_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.bbr.2007.11.021","volume":"188","author":"RJ Melrose","year":"2008","unstructured":"Melrose RJ, Tinaz S, Castelo JMB, Courtney MG, Stern CE. Compromised fronto-striatal functioning in HIV: a fMRI investigation of semantic event sequencing. Behav Brain Res. 2008;188:337\u201347.","journal-title":"Behav Brain Res"},{"key":"679_CR21","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1055\/s-0034-1389161","volume":"45","author":"YJ Crow","year":"2014","unstructured":"Crow YJ, Zaki MS, Abdel-Hamid MS, Abdel-Salam G, Boespflug-Tanguy O, Cordeiro NJV, et al. Mutations in ADAR1, IFIH1, and RNASEH2B presenting as spastic paraplegia. Neuropediatrics. 2014;45:386\u201393.","journal-title":"Neuropediatrics"},{"key":"679_CR22","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/humu.23554","volume":"39","author":"L Ruaud","year":"2018","unstructured":"Ruaud L, Rice GI, Cabrol C, Piard J, Rodero M, van Eyk L, et al. Autosomal-dominant early-onset spastic paraparesis with brain calcification due to IFIH1 gain-of-function. Hum Mutat. 2018;39:1076\u201380.","journal-title":"Hum Mutat"},{"key":"679_CR23","volume":"2015","author":"W Li","year":"2015","unstructured":"Li W, Xin B, Yan J, Wu Y, Hu B, Liu L, et al. SAMHD1 gene mutations are associated with cerebral large-artery atherosclerosis. Biomed Res Int. 2015;2015:739586.","journal-title":"Biomed Res Int"},{"key":"679_CR24","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.1073\/pnas.1014265108","volume":"108","author":"B Xin","year":"2011","unstructured":"Xin B, Jones S, Puffenberger EG, Hinze C, Bright A, Tan H, et al. Homozygous mutation in SAMHD1 gene causes cerebral vasculopathy and early onset stroke. Proc Natl Acad Sci U S A. 2011;108:5372\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"679_CR25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/ng.373","volume":"41","author":"GI Rice","year":"2009","unstructured":"Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM, et al. Mutations involved in Aicardi-Gouti\u00e8res syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet. 2009;41:829\u201332.","journal-title":"Nat Genet"},{"key":"679_CR26","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s12519-022-00545-1","volume":"18","author":"W Wang","year":"2022","unstructured":"Wang W, Wang W, He TY, Zou LP, Li WD, Yu ZX, et al. Analysis of clinical characteristics of children with Aicardi-Goutieres syndrome in China. World J Pediatr. 2022;18:490\u20137.","journal-title":"World J Pediatr"},{"key":"679_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejpn.2013.07.005","volume":"18","author":"G Ramantani","year":"2014","unstructured":"Ramantani G, Maillard LG, Bast T, Husain RA, Niggemann P, Kohlhase J, et al. Epilepsy in Aicardi-Gouti\u00e8res syndrome. Eur J Paediatr Neurol. 2014;18:30\u20137.","journal-title":"Eur J Paediatr Neurol"},{"key":"679_CR28","doi-asserted-by":"crossref","unstructured":"De Giorgis V, Varesio C, Viri M, Giordano L, La Piana R, Tonduti D, et al. The epileptology of Aicardi-Gouti\u00e8res syndrome: electroclinical-radiological findings. 2021;86:197\u2013209.","DOI":"10.1016\/j.seizure.2020.11.019"},{"key":"679_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1469-8749.2008.03225.x","volume":"51","author":"RC Dale","year":"2009","unstructured":"Dale RC, Brilot F, Fagan E, Earl J. Cerebrospinal fluid neopterin in pediatric neurology: a marker of active central nervous system inflammation. Dev Med Child Neurol. 2009;51:317\u201323.","journal-title":"Dev Med Child Neurol"},{"key":"679_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3109\/10408369209114604","volume":"29","author":"D Fuchs","year":"1992","unstructured":"Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci. 1992;29:307\u201341.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"679_CR31","doi-asserted-by":"publisher","first-page":"18291","DOI":"10.1038\/s41598-020-75500-z","volume":"10","author":"M Molero-Luis","year":"2020","unstructured":"Molero-Luis M, Casas-Alba D, Orellana G, Ormazabal A, Sierra C, Oliva C, et al. Cerebrospinal fluid neopterin as a biomarker of neuroinflammatory diseases. Sci Rep. 2020;10:18291.","journal-title":"Sci Rep"},{"key":"679_CR32","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3174\/ajnr.A1694","volume":"30","author":"C Uggetti","year":"2009","unstructured":"Uggetti C, La Piana R, Orcesi S, Egitto MG, Crow YJ, Fazzi E. Aicardi-Gouti\u00e8res syndrome: neuroradiologic findings and follow-up. AJNR Am J Neuroradiol. 2009;30:1971\u20136.","journal-title":"AJNR Am J Neuroradiol"},{"key":"679_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1212\/WNL.0000000000002228","volume":"86","author":"R La Piana","year":"2016","unstructured":"La Piana R, Uggetti C, Roncarolo F, Vanderver A, Olivieri I, Tonduti D, et al. Neuroradiologic patterns and novel imaging findings in Aicardi-Gouti\u00e8res syndrome. Neurology. 2016;86:28\u201335.","journal-title":"Neurology"},{"key":"679_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000518941","volume":"13","author":"B Oleksy","year":"2022","unstructured":"Oleksy B, Mierzewska H, Tryfon J, Wypch\u0142o M, Wasilewska K, Zalewska-Miszkurka Z, et al. Aicardi-Gouti\u00e8res syndrome due to a SAMHD1 mutation presenting with deep white matter cysts. Mol Syndromol. 2022;13:132\u20138.","journal-title":"Mol Syndromol"},{"key":"679_CR35","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s11011-017-9993-4","volume":"32","author":"GMH Abdel-Salam","year":"2017","unstructured":"Abdel-Salam GMH, Abdel-Hamid MS, Mohammad SA, Abdel-Ghafar SF, Soliman DR, El-Bassyouni HT, et al. Aicardi-Gouti\u00e8res syndrome: unusual neuro-radiological manifestations. Metab Brain Dis. 2017;32:679\u201383.","journal-title":"Metab Brain Dis"},{"key":"679_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1055\/s-0030-1255059","volume":"41","author":"GMH Abdel-Salam","year":"2010","unstructured":"Abdel-Salam GMH, El-Kamah GY, Rice GI, El-Darouti M, Gornall H, Szynkiewicz M, et al. Chilblains as a diagnostic sign of aicardi-gouti\u00e8res syndrome. Neuropediatrics. 2010;41:18\u201323.","journal-title":"Neuropediatrics"},{"key":"679_CR37","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/j.1600-0560.2007.00900.x","volume":"35","author":"A Kolivras","year":"2008","unstructured":"Kolivras A, Aeby A, Crow YJ, Rice GI, Sass U, Andr\u00e9 J. Cutaneous histopathological findings of Aicardi-Gouti\u00e8res syndrome, overlap with chilblain lupus. J Cutan Pathol. 2008;35:774\u20138.","journal-title":"J Cutan Pathol"},{"key":"679_CR38","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1525-1470.2009.01055.x","volume":"27","author":"A Juern","year":"2010","unstructured":"Juern A, Robbins A, Galbraith S, Drolet B. Aicardi-Gouti\u00e8res syndrome: cutaneous, laboratory, and radiologic findings: a case report. Pediatr Dermatol. 2010;27:82\u20135.","journal-title":"Pediatr Dermatol"},{"key":"679_CR39","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/ced.13376","volume":"43","author":"S Singh","year":"2018","unstructured":"Singh S, Taneja N, Bala P, Verma KK, Devarajan LSJ. Aicardi-Gouti\u00e8res syndrome: cold-induced acral blemish is not always cryoglobulinaemic vasculitis or chilblain lupus. Clin Exp Dermatol. 2018;43:488\u201390.","journal-title":"Clin Exp Dermatol"},{"key":"679_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.634281","volume":"9","author":"D Wu","year":"2021","unstructured":"Wu D, Fang L, Huang T, Ying S. Case report: Aicardi-Gouti\u00e8res syndrome caused by novel TREX1 variants. Front Pediatr. 2021;9:634281.","journal-title":"Front Pediatr"},{"key":"679_CR41","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1002\/ajmg.a.37944","volume":"170","author":"K Yarbrough","year":"2016","unstructured":"Yarbrough K, Danko C, Krol A, Zonana J, Leitenberger S. The importance of chilblains as a diagnostic clue for mild Aicardi-Gouti\u00e8res syndrome. Am J Med Genet Part A. 2016;170:3308\u201312.","journal-title":"Am J Med Genet Part A"},{"key":"679_CR42","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3389\/fimmu.2020.00985","volume":"11","author":"S Zheng","year":"2020","unstructured":"Zheng S, Lee PY, Wang J, Wang S, Huang Q, Huang Y, et al. Interstitial lung disease and psoriasis in a child with Aicardi-Gouti\u00e8res syndrome. Front Immunol. 2020;11:985.","journal-title":"Front Immunol"},{"key":"679_CR43","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/j.1468-3083.2012.04582.x","volume":"27","author":"M Afshar","year":"2013","unstructured":"Afshar M, Martinez AD, Gallo RL, Hata TR. Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad Dermatol Venereol. 2013;27:771\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"679_CR44","doi-asserted-by":"publisher","first-page":"e770","DOI":"10.1111\/jdv.17440","volume":"35","author":"E Cinotti","year":"2021","unstructured":"Cinotti E, Bertello M, Habougit C, Rongioletti F, Cambazard F, Antoine JC, et al. Aicardi-Gouti\u00e8res syndrome: a possible explanation of angiokeratoma of Mibelli. J Eur Acad Dermatol Venereol. 2021;35:e770\u20132.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"679_CR45","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1086\/513443","volume":"80","author":"G Rice","year":"2007","unstructured":"Rice G, Newman WG, Dean J, Patrick T, Parmar R, Flintoff K, et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Gouti\u00e8res syndrome. Am J Hum Genet. 2007;80:811\u20135.","journal-title":"Am J Hum Genet"},{"key":"679_CR46","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000222430","volume":"219","author":"C G\u00fcnther","year":"2009","unstructured":"G\u00fcnther C, Meurer M, Stein A, Viehweg A, Lee-Kirsch MA. Familial chilblain lupus\u2014a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1. Dermatology. 2009;219:162\u20136.","journal-title":"Dermatology"},{"key":"679_CR47","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1086\/378209","volume":"73","author":"Y Miyamura","year":"2003","unstructured":"Miyamura Y, Suzuki T, Kono M, Inagaki K, Ito S, Suzuki N, et al. Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria. Am J Hum Genet. 2003;73:693\u20139.","journal-title":"Am J Hum Genet"},{"key":"679_CR48","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1210\/jc.2004-0627","volume":"89","author":"C Carella","year":"2004","unstructured":"Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Interferon-\u03b1-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 2004;89:3656\u201361.","journal-title":"J Clin Endocrinol Metab"},{"key":"679_CR49","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1002\/ccr3.3081","volume":"8","author":"C Worth","year":"2020","unstructured":"Worth C, Briggs TA, Padidela R, Balmer E, Skae M. Endocrinopathies in Aicardi Gouti\u00e8res syndrome\u2014a descriptive case series. Clin Case Reports. 2020;8:2181\u20135.","journal-title":"Clin Case Reports"},{"key":"679_CR50","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ejpn.2007.10.005","volume":"12","author":"S Orcesi","year":"2008","unstructured":"Orcesi S, Pessagno A, Biancheri R, La Piana R, Mascaretti M, Rossi A, et al. Aicardi-Gouti\u00e8res syndrome presenting atypically as a subacute leukoencephalopathy. Eur J Paediatr Neurol. 2008;12:408\u201311.","journal-title":"Eur J Paediatr Neurol"},{"key":"679_CR51","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/1744666X.2019.1707663","volume":"16","author":"D Tonduti","year":"2020","unstructured":"Tonduti D, Fazzi E, Badolato R, Orcesi S. Novel and emerging treatments for Aicardi-Gouti\u00e8res syndrome. Expert Rev Clin Immunol. 2020;16:189\u201398.","journal-title":"Expert Rev Clin Immunol"},{"key":"679_CR52","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ymgme.2018.09.004","volume":"125","author":"LA Adang","year":"2018","unstructured":"Adang LA, Frank DB, Gilani A, Takanohashi A, Ulrick N, Collins A, et al. Aicardi Gouti\u00e8res syndrome is associated with pulmonary hypertension. Mol Genet Metab. 2018;125:351\u20138.","journal-title":"Mol Genet Metab"},{"key":"679_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.725868","volume":"9","author":"M Cattalini","year":"2021","unstructured":"Cattalini M, Galli J, Zunica F, Ferraro RM, Carpanelli M, Orcesi S, et al. Case report: the JAK-inhibitor ruxolitinib use in Aicardi-Goutieres syndrome due to ADAR1 mutation. Front Pediatr. 2021;9:725868.","journal-title":"Front Pediatr"},{"key":"679_CR54","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1056\/NEJMc2001362","volume":"383","author":"A Vanderver","year":"2020","unstructured":"Vanderver A, Adang L, Gavazzi F, McDonald K, Helman G, Frank DB, et al. Janus kinase inhibition in the Aicardi-Gouti\u00e8res syndrome. N Engl J Med. 2020;383:986\u20139.","journal-title":"N Engl J Med"},{"key":"679_CR55","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/art.40805","volume":"71","author":"K Meesilpavikkai","year":"2019","unstructured":"Meesilpavikkai K, Dik WA, Schrijver B, van Helden-Meeuwsen CG, Versnel MA, van Hagen PM, et al. Efficacy of baricitinib in the treatment of chilblains associated with Aicardi-Gouti\u00e8res syndrome, a type I interferonopathy. Arthritis Rheumatol. 2019;71:829\u201331.","journal-title":"Arthritis Rheumatol"},{"key":"679_CR56","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1212\/WNL.0000000000004921","volume":"90","author":"K Kothur","year":"2018","unstructured":"Kothur K, Bandodkar S, Chu S, Wienholt L, Johnson A, Barclay P, et al. An open-label trial of JAK 1\/2 blockade in progressive IFIH1-associated neuroinflammation. Neurology. 2018;90:289\u201391.","journal-title":"Neurology"},{"key":"679_CR57","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1056\/NEJMc1810983","volume":"379","author":"GI Rice","year":"2018","unstructured":"Rice GI, Meyzer C, Bouazza N, Hully M, Boddaert N, Semeraro M, et al. Reverse-transcriptase inhibitors in the Aicardi-Gouti\u00e8res syndrome. N Engl J Med. 2018;379:2275\u20137.","journal-title":"N Engl J Med"},{"key":"679_CR58","doi-asserted-by":"crossref","unstructured":"T\u00fcngler V, K\u00f6nig N, G\u00fcnther C, Engel K, Fiehn C, Smitka M, et al. Response to: \u201cJAK inhibition in STING-associated interferonopathy\u201d by Crow et al. Ann Rheum Dis. 2016;75:e76.","DOI":"10.1136\/annrheumdis-2016-210565"},{"key":"679_CR59","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40259-013-0040-7","volume":"27","author":"Y Furumoto","year":"2013","unstructured":"Furumoto Y, Gadina M. The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders. BioDrugs. 2013;27:431\u20138.","journal-title":"BioDrugs"},{"key":"679_CR60","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1093\/rheumatology\/keab860","volume":"61","author":"D Casas-Alba","year":"2022","unstructured":"Casas-Alba D, Darling A, Caballero E, Mensa-Vilar\u00f3 A, Bartrons J, Ant\u00f3n J, et al. Efficacy of baricitinib on chronic pericardial effusion in a patient with Aicardi-Gouti\u00e8res syndrome. Rheumatology (Oxford). 2022;61:e87\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"679_CR61","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/17425255.2019.1673367","volume":"15","author":"Y Wang","year":"2019","unstructured":"Wang Y, De Clercq E, Li G. Current and emerging nonnucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment. Expert Opin Drug Metab Toxicol. 2019;15:813\u201329.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"679_CR62","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.coi.2012.09.007","volume":"24","author":"DB Stetson","year":"2012","unstructured":"Stetson DB. Endogenous retroelements and autoimmune disease. Curr Opin Immunol. 2012;24:692\u20137.","journal-title":"Curr Opin Immunol"},{"key":"679_CR63","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.4049\/jimmunol.1201477","volume":"189","author":"R Baccala","year":"2012","unstructured":"Baccala R, Gonzalez-Quintial R, Schreiber RD, Lawson BR, Kono DH, Theofilopoulos AN. Anti-IFN-\u03b1\/\u03b2 receptor antibody treatment ameliorates disease in lupus-predisposed mice. J Immunol. 2012;189:5976\u201384.","journal-title":"J Immunol"},{"key":"679_CR64","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/14397595.2019.1583832","volume":"30","author":"T Takeuchi","year":"2020","unstructured":"Takeuchi T, Tanaka Y, Matsumura R, Saito K, Yoshimura M, Amano K, et al. Safety and tolerability of sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in Japanese patients with systemic lupus erythematosus: a multicenter, phase 2, open-label study. Mod Rheumatol. 2020;30:93\u2013100.","journal-title":"Mod Rheumatol"},{"key":"679_CR65","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2217\/imt-2016-0090","volume":"9","author":"W Greth","year":"2017","unstructured":"Greth W, Robbie GJ, Brohawn P, Hultquist M, Yao B. Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus. Immunotherapy. 2017;9:57\u201370.","journal-title":"Immunotherapy"},{"key":"679_CR66","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211\u201321.","journal-title":"N Engl J Med"},{"key":"679_CR67","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.4049\/jimmunol.1500969","volume":"195","author":"EE Gray","year":"2015","unstructured":"Gray EE, Treuting PM, Woodward JJ, Stetson DB. Cutting edge: cGAS is required for lethal autoimmune disease in the Trex1-deficient mouse model of Aicardi-Gouti\u00e8res syndrome. J Immunol. 2015;195:1939\u201343.","journal-title":"J Immunol"},{"key":"679_CR68","doi-asserted-by":"publisher","first-page":"7604","DOI":"10.1038\/s41598-020-64348-y","volume":"10","author":"C Wiser","year":"2020","unstructured":"Wiser C, Kim B, Vincent J, Ascano M. Small molecule inhibition of human cGAS reduces total cGAMP output and cytokine expression in cells. Sci Rep. 2020;10:7604.","journal-title":"Sci Rep"},{"key":"679_CR69","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/eji.201747338","volume":"48","author":"F Steinhagen","year":"2018","unstructured":"Steinhagen F, Zillinger T, Peukert K, Fox M, Thudium M, Barchet W, et al. Suppressive oligodeoxynucleotides containing TTAGGG motifs inhibit cGAS activation in human monocytes. Eur J Immunol. 2018;48:605\u201311.","journal-title":"Eur J Immunol"},{"key":"679_CR70","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.4155\/fmc-2017-0322","volume":"10","author":"M Wang","year":"2018","unstructured":"Wang M, Sooreshjani MA, Mikek C, Opoku-Temeng C, Sintim HO. Suramin potently inhibits cGAMP synthase, cGAS, in THP1 cells to modulate IFN-\u03b2 levels. Future Med Chem. 2018;10:1301\u201317.","journal-title":"Future Med Chem"},{"key":"679_CR71","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.cell.2019.01.016","volume":"176","author":"J Dai","year":"2019","unstructured":"Dai J, Huang YJ, He X, Zhao M, Wang X, Liu ZS, et al. Acetylation blocks cGAS activity and inhibits self-DNA-induced autoimmunity. Cell. 2019;176:1447\u201360.e14.","journal-title":"Cell"},{"key":"679_CR72","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1046\/j.1432-1327.2000.01300.x","volume":"267","author":"JL Harcourt","year":"2000","unstructured":"Harcourt JL, Offermann MK. Interferon-alpha synergistically enhances induction of interleukin-6 by double stranded RNA in HeLa cells. Eur J Biochem. 2000;267:2768\u201377.","journal-title":"Eur J Biochem"},{"key":"679_CR73","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s10067-017-3600-2","volume":"36","author":"M Henrickson","year":"2017","unstructured":"Henrickson M, Wang H. Tocilizumab reverses cerebral vasculopathy in a patient with homozygous SAMHD1 mutation. Clin Rheumatol. 2017;36:1445\u201351.","journal-title":"Clin Rheumatol"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-022-00679-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12519-022-00679-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-022-00679-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T16:02:30Z","timestamp":1686499350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12519-022-00679-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":73,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["679"],"URL":"https:\/\/doi.org\/10.1007\/s12519-022-00679-2","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,17]]},"assertion":[{"value":"25 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article. The authors have no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}